Rachana Mandru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachana Mandru has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Christine Yang Zhou
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio (C.Y.Z.)
1 shared publication - Rachel Pauley
Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45221, USA
1 shared publication - Robert M. Burkes
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
1 shared publication
Latest Publications
- Open Access
- 16 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (6) , 1225
Considerations for and Mechanisms of Adjunct Therapy in COPD
Inhaled bronchodilators and corticosteroids, when indicated, form the backbone of COPD therapy. However, over the last decade there has been an emergence of adjunct therapies in oral or inhaled form that are now part of the therapeutic approach to COPD. While these therapies have shown to be beneficial when used in the appropriate instances, there are particular considerations that need to be minded when using these therapies. This review article discussed the mechanism of roflumilast, macrolide antibiotics, other chronic antibiotic regimens, vitamin D supplementation, oral corticosteroids, n-acetylcysteine, and nebulized hypertonic saline, the clinical data behind each of these therapies, adverse events associated with therapy, and the expert recommendations for their utilization. Our goal is to provide a brief but informative and clinically useful review of commonly encountered therapies used in advanced COPD.
- 16 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (6) , 1225
Open AccessConsiderations for and Mechanisms of Adjunct Therapy in COPD
Inhaled bronchodilators and corticosteroids, when indicated, form the backbone of COPD therapy. However, over the last decade there has been an emergence of adjunct therapies in oral or inhaled form that are now part of the therapeutic approach to COPD. While these therapies have shown to be beneficial when used in the appropriate instances, there are particular considerations that need to be minded when using these therapies. This review article discussed the mechanism of roflumilast, macrolide antibiotics, other chronic antibiotic regimens, vitamin D supplementation, oral corticosteroids, n-acetylcysteine, and nebulized hypertonic saline, the clinical data behind each of these therapies, adverse events associated with therapy, and the expert recommendations for their utilization. Our goal is to provide a brief but informative and clinically useful review of commonly encountered therapies used in advanced COPD.